130 Chapter 6 6.7 REFERENCES 1. Duering M, Biessels GJ, Brodtmann A, et al. Neuroimaging standards for research into small vessel disease—advances since 2013. Lancet Neurol. 2023;22(7):602-618. doi: 10.1016/ S1474-4422(23)00131-X 2. Alber J, Alladi S, Bae H, et al. White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): knowledge gaps and opportunities. Alzheimers Dement (NY). 2019;5:107-117. doi:10.1016/j.trci.2019.02.001 3. Benveniste H, Nedergaard M. Cerebral small vessel disease: a glymphopathy? Curr Opin Neurobiol. 2022;72:15-21. doi:10.1016/J.CONB.2021.07.006 4. Bos D, Wolters FJ, Darweesh SKL, et al. Cerebral small vessel disease and the risk of dementia: a systematic review and meta-analysis of population-based evidence. Alzheimers Dement. 2018;14(11):1482-1492. doi:10.1016/j.jalz.2018.04.007 5. De Guio F, DueringM, Fazekas F, et al. Brain atrophy in cerebral small vessel diseases: extent, consequences, technical limitations and perspectives: the HARNESS initiative. J Cereb Blood Flow Metab. 2020;40(2):231-245. doi:10.1177/0271678X19888967 6. Ding J, Sigurðsson S, Jonsson PV, et al. Space and location of cerebral microbleeds, cognitive decline, and dementia in the community. Neurology. 2017;88(22):2089-2097. doi:10.1212/ WNL.0000000000003983 7. Jaarsma-Coes MG, Ghaznawi R, Hendrikse J, et al; Second Manifestations of ARTerial disease SMART Study group. MRI phenotypes of the brain are related to future stroke and mortality in patients with manifest arterial disease: the SMART-MR study. J Cereb Blood Flow Metab. 2020;40(2):354-364. doi:10.1177/0271678X18818918 8. Harris TB, Launer LJ, Eiriksdottir G, et al. Age, gene/environment susceptibility Reykjavik study: multidisciplinary applied phenomics. Am J Epidemiol. 2007;165(9):1076-1087. doi:10.1093/aje/kwk115 9. Saczynski JS, Sigurdsson S, Jonsdottir MK, et al. Cerebral infarcts and cognitive performance: importance of location and number of infarcts. Stroke. 2009;40(3): 677-682. doi:10.1161/ STROKEAHA.108.530212 10. Morris JN, Hawes C, Fries BE, et al. Designing the national resident assessment instrument for nursing homes. Gerontologist. 1990;30(3):293-307. doi:10.1093/GERONT/30.3.293 11. Sveinbjornsdottir S, Sigurdsson S, Aspelund T, et al. Cerebral microbleeds in the population based AGES-Reykjavik study: prevalence and location. J Neurol Neurosurg Psychiatry. 2008;79(9):1002-1006. doi:10.1136/JNNP.2007.121913 12. Zijdenbos AP, Forghani R, Evans AC. Automatic “pipeline” analysis of 3-D MRI data for clinical trials: application to multiple sclerosis. IEEE Trans Med Imaging. 2002;21(10):1280-1291. doi:10.1109/TMI.2002.806283 13. Sigurdsson S, Aspelund T, Forsberg L, et al. Brain tissue volumes in the general population of the elderly: the AGES-Reykjavik Study. Neuroimage. 2012;59(4):3862-3870. doi:10.1016/j. neuroimage.2011.11.024 14. Keller JA, Sigurdsson S, Klaassen K, et al. White matter hyperintensity shape is associated with long-term dementia risk. Alzheimers Dement. 2023;19(12):5632-5641. doi:10.1002/ ALZ.13345 15. Ghaznawi R, Geerlings MI, Jaarsma-Coes MG, et al. The association between lacunes and white matter hyperintensity features on MRI: the SMART-MR study. J Cereb Blood Flow Metab. 2019;39(12):2486-2496. doi:10.1177/0271678X18800463 16. Kassambara A. FactoExtra: extract and visualize the results of multivariate data analyses for R, version 1.0.7. 2020. 17. Maechler M, Rousseeuw P, Struyf A, et al. Package “cluster”: R package version 2.1.2.2021.
RkJQdWJsaXNoZXIy MTk4NDMw